New drug plus pembrolizumab for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cervical cancer that has come back or spread to other parts of the body.
- You have already been treated with pembrolizumab (Keytruda) for at least 6 weeks.
- Your cancer is caused by HPV (human papillomavirus).
- You are in generally good health (able to do daily activities without major issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.